Variant Creutzfeldt-Jakob disease and blood transfusion

Current Opinion in Hematology

Volumn 8, Issue 6, 2001, Pages 372-379

  Turner, Marc L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT THERAPY; BLOOD DISEASE; BLOOD DONOR; BLOOD TRANSFUSION; COMPLEMENT ACTIVATION; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; ELECTROENCEPHALOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT; REVIEW;

ANIMALS; BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; HUMANS; LYMPHOID TISSUE; PRPSC PROTEINS;

EID: 0034765971     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200111000-00010     Document Type: Review

References (95)

1. A new variant of Creutzfeldt-Jakob disease in the UK
2. Variant Creutzfeldt-Jakob disease in UK children: A national surveillance study
3. Variant Creutzfeldt-Jakob disease in an elderly patient
4. New variant Creutzfeldt-Jakob disease: Neurologic features and diagnostic tests
5. New variant Creutzfeldt-Jakob disease: Psychiatric features
6. Variant Creutzfeldt-Jakob disease
7. Recent advances in the pre-mortem diagnosis of Creutzfeldt-Jakob disease
8. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease
9. Diagnosis of new variant Creutzfeldt-Jakob disease
10. Laboratory diagnosis of variant Creutzfeldt-Jakob disease
11. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease
12. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples
13. Typing prion isoforms
14. The transmission of prions to humans
15. New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
16. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution and current concerns
17. BSE transmission to macaques
18. Molecular analysis of prion strain variation and etiology of 'new variant' CJD
19. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent
20. The same prion strain causes vCJD and BSE
21. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy to humans
22. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95
23. The pathogenesis of transmissible spongiform encephalopathy: Routes to the brain and the erection of therapeutic barriers
24. Involvement of the immune system in TSE pathogenesis
25. A crucial role for B cells in neuroinvasive scrapie
26. PrP expression in B lymphocytes is not required for prion neuroinvasion
27. PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice
28. Scrapie pathogenesis in subclinically infected B cell deficient mice
29. Scrapie replication in lymphoid tissues depends on prion protein expressing follicular dendritic cells
30. Tumor necrosis factor alpha deficient, but not interleukin 6 deficient mice resist peripheral infection with scrapie
31. Sites of prion protein accumulation in scrapie-infected mouse spleen revealed by immunoelectron microscopy
32. Prion diseases, blood and immune system: Concerns and reality
33. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie
34. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells
35. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie
36. Complement facilitates early prion pathogenesis
37. Follicular dendritic cells in TSE pathogenesis
38. Sc detection in the preclinical diagnosis of scrapie
39. BSE transmission studies with particular reference to blood
40. BSE and transmission through blood
41. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease
42. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy
43. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans
44. Titer, distribution and transmissibility of blood-borne TSE infectivity
45. The risk of blood borne Creutzfeldt-Jakob disease
46. Infectivity in the blood of mice with a BSE-derived agent
47. Transmission of BSE by blood transfusion in sheep
48. Adaptation of the BSE agent to primates and comparison with Creutzfeldt-Jakob disease: Implications for human health
49. C) expression on hamster, mouse and human blood cells
50. The impact of new-variant Creutzfeldt-Jakob disease on blood transfusion practice
51. European surveillance on Creutzfeldt-Jakob disease: A case control study for medical risk factors
52. Deaths from variant Creutzfeldt-Jakob
53. Incidence of variant Creutzfeldt-Jakob disease in the UK
54. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000
55. Predicting the CJD epidemic in humans
56. Predicted vCJD mortality in Great Britain
57. Prevalence of detectable abnormal prion protein in persons incubating vCJD: Plausible incubation periods and cautious inference
58. Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease
59. Iatrogenic Creutzfeldt-Jakob disease at the millenium
60. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease
61. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease
62. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype
63. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice
64. Retrospective study of prion protein accumulation in tonsil and appendix tissues
65. Assessment of the prevalence of vCJD through testing tonsils and appendices for abnormal prion protein
66. vCJD - Predicting the future
67. Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: Prospective case control study
68. A novel erythroid-specific marker of transmissible spongiform encephalopathies
69. Distribution of cell associated prion protein in normal adult blood determined by flow cytometry
70. The distribution of normal prion protein in human blood
71. Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases
72. Prion protein and developments in its detection
73. Transfusion medicine and spongiform encephalopathy
74. Prion (PrPSc) specific epitope defined by a monoclonal antibody
75. Binding of disease-associated prion protein to plasminogen
76. Monitoring plasma processing steps with a sensitive Western Blot assay for the detection of the prion protein
77. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy
78. Sc molecules with different conformations
79. A cell surface receptor for the prion protein
80. Sc by multispectral ultraviolet fluorescence
81. Ultrasensitive detection of pathologic prion protein aggregates by dual-color scanning for intensely fluorescent targets
82. Leukocyte depletion of blood components
83. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy
84. Studies in the removal of abnormal prion protein by processes used in the manufacture of human plasma products
85. Prions and blood products
86. A direct relation between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins
87. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogues
88. Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies
89. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie and associated prion protein accumulation
90. Reversion of prion protein conformational changes by synthetic sheet breaker peptides
91. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice
92. Dapsone to delay symptoms in Creutzfeldt-Jakob disease
93. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies